ZYDUSLIFE Zydus Lifesciences Q4 FY25 results (Jan–Mar 2025) and concall
Zydus Lifesciences concluded FY25 on a strong note, reporting robust double-digit growth in revenues and achieving its highest-ever operating profit and margins. The US business, India formulations, and consumer wellness segments all contributed positively. While the company anticipates continued growth across geographies, FY26 EBITDA margins are guided lower due to competitive pressures on key products and increased R&D. The company is actively expanding its specialty and innovation pipeline, including new product launches and strategic acquisitions like Amplitude Surgical SA.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 2,621 | 2,516 | 5,820 |
| EBITDA | 942 | 648 | 3,773 |
| Net profit | 790 | 471 | 2,814 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
